摘要
目的分析阿立唑哌、利培酮对精神分裂症患者血清尿酸水平的影响。方法便利选取2017年2月—2018年5月该院收治的精神分裂症患者120例,随机单双法数法分为对照组60例,主要为进行利培酮治疗,观察组60例,进行阿立唑哌治疗,分析患者血清尿酸水平不良反应等变化。结果治疗前,两组患者血清尿酸水平差异无统计学意义(t=1.882,P>0.05);观察组患者治疗后4周血清尿酸水平为(273.60±8.60)μmoml/L、治疗后6周为(268.50±4.60)μmoml/L,明显低于对照组,差异有统计学意义(t=20.772、33.854,P<0.05);观察组患者不良反应发生率为6.67%,对照组为11.67%,差异无统计学意义(χ^(2)=0.900,P>0.05);观察组患者治疗后总有效率为98.33%,高于对照组85.00%,差异有统计学意义(χ^(2)=6.981,P<0.05)。结论为精神分裂症患者采用阿立唑哌、利培酮进行治疗时均可有效改善血清尿酸水平,且治疗安全性较高,有临床应用价值。
Objective To analyze the effects of aripipramide and risperidone on serum uric acid levels in patients with schizophrenia.Methods A total of 120 patients with schizophrenia admitted to the hospital from February 2017 to May 2018 were conveniently selected.They were randomly divided into 60 cases in the control group by the odd and even method,mainly receiving risperidone treatment,and 60 cases in the observation group,with rizopir treatment,analysis of the patient's serum uric acid level adverse reactions and other changes.Results There was no statistically significant difference in serum uric acid levels between the two groups before treatment(t=1.882,P>0.05);in the observation group,the serum uric acid level was(273.60±8.60)μmoml/L at 4 weeks after treatment,and(268.50±4.60)μmoml/L at 6 weeks after treatment,which were lower than the control group(t=20.772,33.854,P<0.05);the adverse reaction occurrence rate of the observation group was 6.67%,and the control group was 11.67%,the difference was not statistically significant(χ^(2)=0.900,P>0.05);the observation group after treatment of the total effective rate was 98.33%,which was higher than that of the control group85.00%,and the difference was statistically significant(χ^(2)=6.981,P<0.05).Conclusion The treatment of schizophrenia patients with aripipramide and risperidone can effectively improve the serum uric acid level,and the treatment is safer and has clinical application value.
作者
张鹏飞
罗玉霞
ZHANG Pengfei;LUO Yuxia(The Second Department of Psychiatry,Oasis Hospital,Shihezi City,Xinjiang,Shihezi,Xinjiang Uygur Autonomous Region,832000 China)
出处
《中外医疗》
2021年第16期23-25,29,共4页
China & Foreign Medical Treatment
